Cargando…
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
BACKGROUND: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but their role in glioblastoma is uncertain. OBJECTIVE: To review t...
Autor principal: | Omuro, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491432/ https://www.ncbi.nlm.nih.gov/pubmed/35976319 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S129 |
Ejemplares similares
-
Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019) -
Venous thromboembolic events in glioblastoma patients: An epidemiological study
por: Eisele, Amanda, et al.
Publicado: (2022) -
Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015) -
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022) -
Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study)
por: Booth, Thomas C., et al.
Publicado: (2020)